ClinicalTrials.gg
CompletedNCT05742919Updated Jun 11, 2024

A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men

A Phase 1 interventional study of NNC0194-0499 and NNC0194-0499 in Non-alcoholic Fatty Liver Disease, sponsored by Novo Nordisk A/S. Completed at 1 site in China. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S — 1 open to participants now, 4 under way, 3 of them phase 3. Non-alcoholic Fatty Liver Disease · Novo Nordisk A/S.

Enrollment
16th of 17
24 · median 71
Started
2023
with 5 others
Phase 1
7 of 18
none open now
Registered
12th of 18
by date

Among the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2023, is one of 7 in phase 1, and was the 12th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

1 of the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 20 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study looks at how a new study medicine called NNC0194-0499 behaves in the body of Chinese men. Three different dose levels will be tested. Participant will get only one of the three different dose levels of NNC0194-0499. Which dose participant will get will be decided by chance. NNC0194-0499 is a medicine under clinical investigation. It means that the medicine has not yet been approved by the health authorities. Participant will get 1 or 2 injections of the study medicine. It will be injected with a needle into a skin fold on stomach. The study will last for a maximum of 64 days. Participant will not be able to take part in the study if the study doctor considers there is a risk for participant's health.

03

Conditions studied

  • Non-alcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  • Chinese male aged 20-55 years (both inclusive) at the time of signing informed consent.
  • (BMI) between 23.0 and 34.9 kilograms per meter square (kg/m\^2) (both inclusive).
  • Body weight greater than or equal to 60 kg.
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention or related products.
  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    NNC0194-0499 12 mg

    Participants will receive a single subcutaneous (s.c.) dose of 12 milligrams (mg) NNC0194-0499 on Day 1.

    Drug: NNC0194-0499

  • Experimental
    NNC0194-0499 30 mg

    Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.

    Drug: NNC0194-0499

  • Experimental
    NNC0194-0499 96 mg

    Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.

    Drug: NC0194-0499

Interventions

  • Participants will receive a single s.c. dose of 12 mg NNC0194-0499 on Day 1.

  • Participants will receive a single s.c. dose of 30 mg NNC0194-0499 on Day 1.

  • DrugNC0194-0499

    Participants will receive a single s.c. dose of 96 mg NNC0194-0499 on Day 1.

06

What researchers measure

Primary outcomes

  1. AUC0-∞, NNC0194-0499: The area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity after a single dose

    Measured in nanomoles\*hours per liter (nmol h/L).

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

Secondary outcomes

  1. AUC0-168h, NNC0194-0499: The area under the NNC0194-0499 serum concentration-time curve from time 0 to 168 hours after a single dose

    Measured in nmol h/L.

    Time frame: From Day 1 (pre-dose) until Day 7 (168 hours)

  2. Cmax, NNC0194-0499: The maximum concentration of NNC0194- 0499 in serum

    Measured in nmol/L.

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  3. tmax, NNC0194-0499: The time from dose administration to maximum serum concentration of NNC0194-0499

    Measured in hours.

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  4. t1/2, NNC0194-0499: The terminal half-life of NNC0194-0499

    Measured in hours.

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  5. CL/FNNC0194-0499: The apparent total serum clearance of NNC0194-0499

    Measured in liters per hour (L/h).

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  6. Vz/FNNC0194-0499: The apparent volume of distribution of NNC0194-0499 in the terminal phase

    Measured in liters (L).

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  7. Relative change in triglycerides

    Measured in Percent change.

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  8. Relative change in high-density lipoprotein (HDL) cholesterol

    Measured in Percent change.

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  9. Relative change in low-density lipoprotein (LDL) cholesterol

    Measured in Percent change.

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

07

Study locations

1 site
  • Jinan Central Hospital
    Jinan, Shandong 250062, China
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jun 2023, 3 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Feb 24, 2023
StartActual
Feb 16, 2023
Primary completionActual
Jun 13, 2023
CompletionActual
Jun 13, 2023
Last update
Jun 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05742919
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Feb 16, 2023
Primary completion
Jun 13, 2023
Completion
Jun 13, 2023
Last update
Jun 11, 2024

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zalfermin

Start the discussion